La catena delle opzioni mostra i dati chiave delle opzioni azionarie di BrightSphere Investment a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per BrightSphere Investment..

BrightSphere Investment (NYSE:BSIG) Azioni, Catena delle Opzioni

BrightSphere Investment

BrightSphere Investment Group Inc is a diversified, multi-boutique asset management company. The company's diverse affiliates offer alpha-generating investment products to investors around the world. Its reportable segment includes Quant and Solutions, which comprises versatile, tailored strategies that leverage data and technology in a computational, factor-based investment process across a range of asset classes in developed and emerging markets, including non-U.S. and small-cap equities, as well as managed volatility, ESG, multi-asset, equity alternatives, and long/short strategies. Its affiliates offer products in the U.S, international and emerging markets equities; U.S. fixed income; and alternative investments, including timber and secondary Funds.

BrightSphere Investment Group Inc. Common Stock

BrightSphere Investment Group Inc

News

RVNC

Revance Therapeutics Extends Tender Offer Deadline For Merger With Crown Laboratories To December 3, 2024 Amid Ongoing Discussions

JFBR

Jeffs' Brands Announces Trademark Registration Approval For Wellution, A Wellness And Personal Care Brand (49%) From The USPTO - Wellution's Skin And Hair Care Product Lines

Volkswagen (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>)&nbsp;will leverage <a href="https://www.benzinga.com/24/11/41934150/rivian-shares-rise-13-in-pre-market-after-volkswagen-increases-planned-investment-to-58b">its partnership with</a> Rivian&nbsp;Automotive Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) to power its upcoming flagship electric vehicle, codenamed "Project Trinity."
What Happened: This collaboration is part of a $5.8 billion joint venture aimed at integrating Rivian&#8217;s advanced architecture into Volkswagen&#8217;s future models.
According <a href="https://insideevs.com/news/742492/vw-project-trinity-rivian-sdv/">to</a> InsideEVs, Project Trinity, initially delayed, is set to feature Level 4 autonomous driving capabilities. The delay allows Volkswagen to focus on launching an&nbsp;electrified version of the Golf,&nbsp;described as a more &#8220;iconic product.&#8221;
The Golf EV is expected to debut in 2029, with Trinity following at a later date.
Volkswagen CEO Thomas Schafer confirmed the partnership with Rivian during a media roundtable, emphasizing the importance of the new software-defined vehicle architecture.
"We&nbsp;decided on how to do&nbsp;the software-defined vehicle. It&nbsp;will happen with Rivian, the&nbsp;joint venture, where we put the new electric electronics architecture together," said Schafer.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42185887/astrophysicist-neil-degrasse-tyson-dismisses-musks-vision-to-build-self-sustaining-city-on-mars?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Astrophysicist Neil deGrasse Tyson Dismisses Elon Musk&#8217;s Mars Vision: SpaceX CEO Hits Back, Says &#8216;They Really Don't Get It'</a>
While Project Trinity is not intended as a mass-market vehicle, it remains a crucial part of Volkswagen&#8217;s strategy to rejuvenate its brand.
The new architecture will first appear in&nbsp;Porsche&nbsp;and&nbsp;Audi&nbsp;models by 2027, eventually extending across the Volkswagen family, including luxury SUVs and compact cars.
Why It Matters: The partnership between Volkswagen and Rivian marks a strategic move for both companies.
The joint venture, officially <a href="https://www.benzinga.com/24/11/41934150/rivian-shares-rise-13-in-pre-market-after-volkswagen-increases-planned-investment-to-58b">launched earlier this month</a>, involves a $5.8 billion investment from Volkswagen, up from the previously announced $5 billion. This increase in investment underscores the importance of the collaboration for Rivian, providing a much-needed boost to its financial stability and growth potential.
The joint venture aims to advance electrical and electronic architecture technology, focusing on electronic control units, network infrastructure, and associated software. This partnership is expected to enhance Rivian&#8217;s capital roadmap, aiding in future growth and vertical integration of its software and electrical systems, according to&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41938838/rivians-deal-with-volkswagen-will-help-ev-giant-navigate-the-ship-in-stormy-waters-says-top-analyst-maintains-outperform-rating-with-20-target">analysts</a>&nbsp;at Wedbush.
However, the deal has not been without controversy, <a href="https://www.benzinga.com/news/24/09/40772132/volkswagens-5b-deal-with-rivian-leaves-software-arm-cariad-workers-frustrated-ceo-left-out-report">reportedly causing discontent</a> among employees at Volkswagen&#8217;s software division, Cariad.
Price Action: Rivian stock closed at $12.22 on Wednesday, surging 5.8%. In premarket trading on Friday, the stock was up 1.5%. Year-to-date, the Rivian stock has declined by 42%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Analysts are bullish on Rivian, with the consensus rating being ‘Buy' on the EV giant's stock. The highest price target is $28, while the lowest is $11. The consensus price target is $16.17, which implies a 32% upside.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/RIVN/analyst-ratings"><img loading="lazy" decoding="async" width="948" height="356" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29060011/Rivian-Volkswagen.jpg" alt="" class="wp-image-669845" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29060011/Rivian-Volkswagen.jpg 948w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29060011/Rivian-Volkswagen-300x113.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29060011/Rivian-Volkswagen-768x288.jpg 768w" sizes="(max-width: 948px) 100vw, 948px" /></a></figure>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42188994/amid-trumps-plans-to-impose-25-tariffs-mexico-fears-byd-new-factory-in-country-would-send-wrong-message-investments-from-china-have-to-be-analyzed-with-extreme-caution?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Amid Trump&#8217;s Plans To Impose 25% Tariffs, Mexico Fears BYD's New Factory In Country Would Send Wrong Message</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

Global

Markets

Tech

RIVN

VWAGY

Volkswagen Taps Rivian Partnership For Upcoming Flagship EV 'Project Trinity'

RDNT

RadNet's DeepHealth Subsidiary Expands FDA Clearance For SmartMammo Solution; Clearance Enables  RadNet's DeepHealth and GE HealthCare Collaboration To Bring Together The SmartMammo And Senographe Pristina Solutions For Breast Cancer Diagnosis

On Wednesday, Applied Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) received an FDA Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42224414/applied-therapeutics-receives-complete-response-letter-from-u-s-fda-regarding-new-drug-application" rel="noreferrer noopener">for Classic Galactosemia</a>.
Galactosemia is a rare genetic metabolic disease resulting in an inability to metabolize the simple sugar galactose. When not appropriately metabolized, galactose is converted to the toxic metabolite, galactitol, which causes neurological complications.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40921732/applied-therapeutics-stock-soars-as-fda-scraps-panel-meeting-for-its-inherited-metabolic-disorder" rel="noreferrer noopener">Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug</a>
The CRL indicates that the FDA completed its review of the application and determined that it is unable to approve the NDA in its current form, citing deficiencies in the clinical application.
Applied Therapeutics is reviewing the FDA feedback. It plans to immediately request a meeting to discuss the requirements for a potential resubmission of the NDA or appeal of the decision and appropriate next steps.
In Phase 3 registrational ACTION-Galactosemia Kids study in children with Galactosemia aged 2-17, treatment with govorestat demonstrated clinical benefit on activities of daily living, behavioral symptoms, cognition, fine motor skills, and tremor.
Govorestat also significantly reduced plasma galactitol levels in adults and children with Galactosemia.
Govorestat is also being developed for Sorbitol Dehydrogenase (SORD) Deficiency, a rare and progressive neuromuscular disease. The company expects to submit an NDA early in the first quarter of 2025.
William Blair stated that they were confident in the approval of govorestat ahead of its PDUFA date, given strong clinical data showing its effectiveness for a rare disease with no available treatments. However, the FDA&#8217;s rejection was unexpected and disappointing.
With limited details in the CRL, the next steps for govorestat in treating galactosemia remain unclear, including whether another clinical trial will be required.
As a result, William Blair has lowered its probability of success for the galactosemia program to 30% and delayed the projected U.S. launch to the fourth quarter of 2025, pending further clarification.
Despite this setback, William Blair maintained its Outperform rating, noting that the CRL likely doesn&#8217;t impact the company&#8217;s other program targeting SORD.
They emphasized that the SORD clinical trial met its key goals and offered a stronger data package. Additionally, the FDA&#8217;s alignment on an accelerated approval pathway for SORD suggests that, if granted priority review, govorestat could still begin generating revenue by late 2025.
Price Action: APLT stock is down 67.2% at $2.81 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42222191/donald-trump-nominates-pandemic-critic-jay-bhattacharya-tapped-to-reshape-national-institutes-of-health-that-oversees-budget-of-48-billion" target="_blank" rel="noreferrer noopener">Trump Taps Pandemic Lockdown Critic Jay Bhattacharya To Overhaul NIH</a></li>
</ul>
Illustration of Phrama lab worker created with MidJourney.

Analyst Color

Biotech

Health Care

Reiteration

Analyst Ratings

Movers

Trading Ideas

General

APLT

Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Application

Offerings

Management

Insider Trades

BSLK

Bolt Projects Holdings On Wednesday Announced Private Placement With CEO and Other Officers Of 1.06M Shares At $0.34/Share For $360K Gross Proceeds; Closing Expected December 2, 2024

MicroStrategy Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) experienced a notable 4.44% increase in its share price during pre-market trading on Friday as per <a href="https://pro.benzinga.com/">Benzinga Pro</a>. This rise aligns with Bitcoin&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recovery from its recent dip.
What Happened: Earlier this week, Bitcoin had dropped to $92,000 but was trading at $96,596.96 by 5:26 a.m. ET. The cryptocurrency&#8217;s resurgence seems to have positively impacted MicroStrategy&#8217;s stock performance.
MicroStrategy&#8217;s consensus price target stands at $449.5, based on assessments from 12 analysts. The highest target of $690 was set&nbsp;by BTIG on December 11,&nbsp;2023, while the lowest, $140, was&nbsp;issued by Jefferies on Nov.&nbsp;10, 2022.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42206056/bitcoin-ethereum-dogecoin-tumble-as-diamond-hands-lock-in-gains-analyst-anticipates-strong-buyback-pressure-to-follow-sell-pressure?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Tumble As &#8216;Diamond Hands&#8217; Lock In Gains: Top Analyst Anticipates BTC Rebound</a>
As per Benzinga Pro, the consensus price target for MSTR is $449.5 based on the ratings of 12 analysts. The most recent analyst ratings for MicroStrategy were provided by TD Cowen, Barclays, and Benchmark on Nov. 25. These ratings suggest an average price target of $563.33, indicating a potential upside of 38.72% for the company.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/MSTR/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29054824/Screenshot-2024-11-29-at-4.18.06%E2%80%AFPM-1024x398.png" alt="" class="wp-image-669815" /></a></figure>
Why It Matters: MicroStrategy&#8217;s stock performance is closely tied to Bitcoin&#8217;s fluctuations due to its substantial investment in the cryptocurrency. The company&#8217;s strategy of acquiring and holding Bitcoin has been both praised and criticized. Recently,&nbsp;economist and market strategist Peter Schiff <a href="https://www.benzinga.com/24/11/42237876/peter-schiff-predicts-microstrategys-bankruptcy-due-to-bitcoin-investment-strategy">predicted potential bankruptcy</a> for MicroStrategy due to its Bitcoin investment approach. In an interview with Kitco News, Schiff described MicroStrategy as a &#8220;great short&#8221; and suggested that the company&#8217;s strategy could ultimately lead to bankruptcy. Schiff&#8217;s comments highlight the risks associated with MicroStrategy&#8217;s heavy reliance on Bitcoin&#8217;s market performance.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/11/42228090/bitcoin-ethereum-dogecoin-surge-as-traders-raise-risk-appetite-ahead-of-thanksgiving-analyst-says-eth-could-jump-to-highs-not-seen-since-late-2021?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Surge As Traders Raise Risk Appetite Ahead Of Thanksgiving: Analyst Sets Mid-Term Price Target For ETH At $6K</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

$BTC

MSTR

MicroStrategy Shares Jumps In Friday Pre-Market As Bitcoin Rebounds To $96,000: Consensus Price Target Reveals Over 15% Upside For MSTR

On Wednesday, Envirotech Vehicles, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTV#NASDAQ">EVTV</a>) disclosed that it delivered two demonstration electric delivery vans to FedEx Delivery Service Partners, including <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac42227275/envirotech-vehicles-inc-nasdaq-evtv-announces-delivery-of-electric-vans-to-fedex" rel="noreferrer noopener">Dreaming Green Corp. in Connecticut</a>.
These mid-roof electric vans will deliver packages to homes and businesses in Connecticut.
With average gasoline prices in Connecticut exceeding $3.00 per gallon and diesel approaching $3.70, Envirotech&#8217;s electric delivery vehicles present an appealing option for fleet-reliant businesses.
Dreaming Green Corp.&#8217;s owner Nelson Pinhancos said, &#8220;We are excited to begin testing the Envirotech electric delivery van. We estimate a monthly savings of $1,800 in fuel and maintenance costs. And the fact we will be generating zero emissions while serving our customers is something we are proud of as a company.&#8221;
&#8220;We expect this test program to be a success. And we look forward to then scaling up our Envirotech electric fleet. Other FedEx DSPs have already shown interest in joining us.&#8221;
Phil Oldridge, CEO of Envirotech, stated, &#8220;Envirotech is proud to serve business owners from California to Connecticut as we help them reduce their operating costs and increase their on-time delivery performance.&#8221; &#8220;First mile, last mile delivery companies know how impactful monthly saving of one to two thousand dollars per vehicle is for their bottom line. And successful deliveries with no emissions are a mark of pride for every owner of an Envirotech vehicle.&#8221;
This week, Envirotech Vehicles disclosed plans to access $25 million in funding from <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac42201399/envirotech-vehicles-inc-nasdaq-evtv-expects-to-access-25-million-in-funding-from-yorkville-adviso" rel="noreferrer noopener">Yorkville Advisors Global LP</a>.
Price Action: EVTV shares closed higher by 6.67% at $1.44 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42240301" target="_blank" rel="noreferrer noopener">Elon Musk Lauds Apple AirPods Pro 2&#8217;s Hearing Aid Feature As Tim Cook Highlights The Affordable Solution To What Otherwise Costs Up To $7,000</a></li>
</ul>

Small Cap

EVTV

FedEx Delivery Service Partners Test Envirotech Electric Vans In Connecticut: Details

Nordic American Tankers Reports Strong Q3 2024 with $8.7M Profit, $125M in New Long-Term Contracts, and 109th Consecutive Dividend; Fleet Expansion Planned

Macro Economic Events

Econ #s

Economics

INDA

India Gross Domestic Product Quarterly (YoY) For Q2 5.4% Vs. 6.5% Est.; 6.7% Prior

Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) has introduced a new AI model, QwQ-32B-Preview, which is positioned as a competitor to Microsoft Corp.-backed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) OpenAI&#8217;s o1 <a href="https://www.benzinga.com/top-stories/24/09/40842891/openai-unveils-o1-model-a-step-closer-to-human-like-ai-but-not-without-flaws">reasoning model</a>.
What Happened: Developed by Alibaba&#8217;s Qwen team, QwQ-32B-Preview boasts 32.5 billion parameters, enabling it to handle prompts up to 32,000 words.
This model is one of the few available under a permissive license, allowing for download and use, the company stated in a blog post on Thursday.
It reportedly outperforms OpenAI&#8217;s o1-preview and o1-mini models on specific benchmarks, such as the AIME and MATH tests. These tests evaluate AI models&#8217; performance in logic puzzles and math problems.
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42169194/joby-gets-toyotas-500m-dollar-lift-evtol-pioneer-making-new-highs?itm_source=parsely-api">Joby Gets Toyota&#8217;s $500M Dollar Lift: eVTOL Pioneer Making New Highs</a>
Despite its strengths, QwQ-32B-Preview has limitations. Alibaba acknowledges potential issues like unexpected language switches and underperformance in tasks requiring common sense reasoning.
The model&#8217;s reasoning capabilities allow it to fact-check itself, reducing errors but increasing solution time.
QwQ-32B-Preview is available on the AI development platform Hugging Face.
However, only certain components are released, limiting full replication or insight into its workings. The model&#8217;s responses align with Chinese regulatory standards, avoiding politically sensitive topics.
The development was first <a href="https://techcrunch.com/2024/11/27/alibaba-releases-an-open-challenger-to-openais-o1-reasoning-model/">spotted</a> by TechCrunch.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: The introduction of Alibaba&#8217;s QwQ-32B-Preview comes at a time when OpenAI is making significant strides in the AI sector. Last month, OpenAI&#8217;s valuation <a href="https://www.benzinga.com/news/24/10/41149788/openai-valuation-soars-to-157b-in-latest-funding-round">soared to $157 billion </a>following a successful funding round.&nbsp;
Earlier this week, it was reported that SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) has increased its stake in OpenAI through a <a href="https://www.benzinga.com/markets/equities/24/11/42227972/softbank-secures-bigger-openai-stake-with-1-5b-employee-share-buyout-report">$1.5 billion employee share buyout</a>.
OpenAI is also reportedly exploring the <a href="https://www.benzinga.com/markets/24/11/42130303/chatgpt-parent-openai-considers-building-its-own-web-browser-to-challenge-googles-search-monopoly-following-doj-push-to-break-up-chrome-dominance">development of its own web browser</a> to challenge Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary Google&#8217;s Chrome browser, following a push from the U.S. Department of Justice to divest it.
Price Action: Currently, Alibaba shares are up 0.27% to $86.82 in pre-market trading on Friday, following a 1.66% rise to $86.59 during Wednesday&#8217;s regular session, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42053396/why-chinese-tech-giants-alibaba-bytedance-and-meituan-are-expanding-their-ai-footprints-in-silicon-valley-amid-us-efforts-to-block-progress?itm_source=parsely-api">China&#8217;s Tech Giants Alibaba, ByteDance, And Meituan Are Expanding Their Silicon Valley AI Footprints Amid US Efforts To Block Progress: Here&#8217;s Why</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Media

BABA

GOOG

GOOGL

MSFT

SFTBF

Alibaba's New AI Model Outperforms OpenAI's o1 In Specific Benchmarks, Now Available For Free Download

BWLP

BW LPG Says It Takes Delivery Of Vessel BW Levant From Avance Gas; Five Of The 12 VLGCs Are Now Delivered

Eurozone Consumer Price Index (YoY) Preliminary For November 2.3% Vs. 2.3% Est.; 2.0% Prior

Eurozone Consumer Price Index (MoM) Preliminary For November -0.3% Vs. 0.3% Prior

Eurozone Core Consumer Price Index (YoY) Preliminary For November 2.7% Vs. 2.8% Est.; 2.7% Prior

Germany Unemployment Rate For November Unchanged At 6.1%

Germany Unemployment Change For November 7K Vs. 20K Est.; 27K Prior

Tesla Inc. CEO Elon Musk endorsed Apple Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) latest health technology innovation, responding &#8220;This is cool&#8221; to CEO Tim Cook&#8216;s announcement of AirPods Pro 2&#8217;s <a href="https://www.benzinga.com/news/24/09/40786879/apples-airpods-pro-2-bring-clinical-grade-hearing-aid-without-the-stigma-or-high-cost-heres-what-peo">new hearing aid capabilities</a>.
What Happened: Cook had shared his pride in Apple&#8217;s teams developing &#8220;powerful technologies that are improving people&#8217;s lives,&#8221; specifically highlighting the AirPods Pro 2&#8217;s personalized hearing aid feature. This development comes as Apple transforms its popular wireless earbuds into <a href="https://www.benzinga.com/news/24/09/40786879/apples-airpods-pro-2-bring-clinical-grade-hearing-aid-without-the-stigma-or-high-cost-heres-what-peo">clinical-grade hearing assistance devices</a>.
The new functionality addresses a significant global health challenge, with the World Health Organization estimating that 1.5 billion people worldwide suffer from hearing loss. Traditional prescription hearing aids typically cost between $2,000 and $7,000, making them <a href="https://www.benzinga.com/news/24/09/40786879/apples-airpods-pro-2-bring-clinical-grade-hearing-aid-without-the-stigma-or-high-cost-heres-what-peo">inaccessible to many potential users</a>.
Apple&#8217;s comprehensive hearing health solution includes active hearing protection, an at-home hearing test, and hearing aid capabilities that adjust sound in real time based on personalized hearing profiles.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is cool
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1862332184645779458?ref_src=twsrc%5Etfw">November 29, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/24/11/42237670/meta-tiktok-snapchat-could-face-32m-fines-as-australia-enforces-social-media-ban-for-under-16s-while-exempting-youtube">Meta, TikTok, Snapchat Could Face $32M Fines As Australia Enforces Social Media Ban For Under-16s</a>
Why It Matters: The features are awaiting marketing authorization from health authorities, including the U.S. Food and Drug Administration, and are expected to launch <a href="https://www.benzinga.com/news/24/09/40786879/apples-airpods-pro-2-bring-clinical-grade-hearing-aid-without-the-stigma-or-high-cost-heres-what-peo">this fall in over 100 markets</a>.
This development <a href="https://www.benzinga.com/news/22/11/29780663/apple-airpods-pro-as-hearing-aids-it-may-be-closer-than-you-think">builds on earlier research</a> published in iScience journal, which found that AirPods Pro met four out of five standards for personal sound amplification products. 
The AirPods line remains crucial to Apple&#8217;s wearables segment, which generated $9.04 billion in <a href="https://www.benzinga.com/news/earnings/24/10/41666494/apple-q4-earnings-revenue-beat-eps-beat-installed-base-hits-new-highs-iphone-sales-rise-as-apple-in">fiscal fourth-quarter revenue</a>. 
While Apple maintains its leadership in the true wireless stereo market with a 17% share, this represents a significant decrease from its 48.1% share in 2019, reflecting <a href="https://www.benzinga.com/tech/24/11/42182829/apple-could-keep-airpods-max-headphones-around-without-meaningfully-updating-them-says-analyst-heres-why">increased competition in the space</a>.
The innovation comes as Apple continues to dominate the tech sector, with the company reporting overall fiscal fourth-quarter revenue of $94.9 billion, <a href="https://www.benzinga.com/tech/24/11/42182829/apple-could-keep-airpods-max-headphones-around-without-meaningfully-updating-them-says-analyst-heres-why">exceeding analyst expectations</a> and demonstrating strong performance across its product ecosystem.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42238773/cathie-wood-sees-tesla-as-largest-ai-project-on-earth-heres-why-shes-not-worried-about-tech-investments">Cathie Wood Sees Tesla As &#8216;Largest AI Project On Earth&#8217; — Here&#8217;s Why She&#8217;s Not Worried About Tech Investments</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a><a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

AAPL

Elon Musk Lauds Apple AirPods Pro 2's Hearing Aid Feature As Tim Cook Highlights The Affordable Solution To What Otherwise Costs Up To $7,000

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) with a Buy and maintains $30 price target.

Price Target

OTLK

HC Wainwright & Co. Reiterates Buy on Outlook Therapeutics, Maintains $30 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) with a Neutral and maintains $7 price target.

AGEN

HC Wainwright & Co. Reiterates Neutral on Agenus, Maintains $7 Price Target

Tracking John Paulson's Paulson & Company Portfolio - Q2 2024 Update

BrightSphere Investment Group ( ($BSIG) ) has issued an update. BrightSphere Investment Group Inc. is set for a major leadership and branding trans...

BrightSphere's Leadership Shift and Rebranding to Acadian

Michael Cyprys, an analyst from Morgan Stanley, maintained the Hold rating on BrightSphere Investment Group (BSIG – Research Report). The associate...

Hold Rating on BrightSphere Amidst CEO Change and Strategic Shifts

Victory Capital upgraded, BrightSphere Investment downgraded at Morgan Stanley

Reports Q3 revenue $123.1M, consensus $111.6M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news...

BrightSphere reports Q3 EPS 59c, consensus 48c

BrightSphere Investment GAAP EPS of $0.45, revenue of $123.1M beats by $10.6M

BrightSphere Investment Group Inc. (BSIG) Q3 2024 Earnings Call Transcript

BrightSphere Investment Group Inc. 2024 Q3 - Results - Earnings Call Presentation

Brightsphere Investment Group ( ($BSIG) ) has released its Q3 earnings. Here is a breakdown of the information Brightsphere Investment Group presen...

BrightSphere Investment Group's Q3 2024 Earnings Overview

Evercore ISI analyst Glenn Schorr maintained a Hold rating on BrightSphere Investment Group (BSIG – Research Report) today and set a price target o...

Evercore ISI Remains a Hold on BrightSphere Investment Group (BSIG)

BSIG

ETHE

FBTC

FMCC

FMCCG

FMCCH

FMCCI

FMCCJ

FMCCK

FMCCL

FMCCM

FMCCN

FMCCO

FMCCP

FMCCS

FMCCT

FMCKI

FMCKJ

FMCKK

FMCKL

FMCKM

FMCKN

FMCKO

FMCKP

FNMA

FNMAG

FNMAH

FNMAI

FNMAJ

FNMAK

FNMAL

FNMAM

FNMAN

FNMAO

FNMAP

FNMAS

FNMAT

FNMFM

FNMFN

FNMFO

FREGP

FREJN

FREJO

FREJP

IBIT

MDGL

PPTA

THRY

VCTR

Press Releases

BrightSphere to Report Financial and Operating Results for the Fourth Quarter Ended December 31, 2023

BrightSphere Reports Financial and Operating Results for the Fourth Quarter Ended December 31, 2023

BrightSphere to Report Financial and Operating Results for the First Quarter Ended March 31, 2024

BrightSphere Reports Financial and Operating Results for the First Quarter Ended March 31, 2024

BrightSphere to Report Financial and Operating Results for the Second Quarter Ended June 30, 2024

BrightSphere Reports Financial and Operating Results for the Second Quarter Ended June 30, 2024

BrightSphere Appoints Kelly Young as President and Chief Executive Officer, Announces Rebranding as Acadian Asset Management Inc.

BrightSphere to Report Financial and Operating Results for the Third Quarter Ended September 30, 2024

BrightSphere Reports Financial and Operating Results for the Third Quarter Ended September 30, 2024

Comments

BrightSphere Investment

BrightSphere Investment (BSIG) Opzioni

BrightSphere Investment (NYSE:BSIG) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO